Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel (Q44071332)

29 November 2017

title

Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel (English)

1 reference

29 November 2017

Bruce R Carr

1 reference

29 November 2017

Anthony DelConte

series ordinal

1 reference

29 November 2017

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

397-402

1 reference

The perimenopausal transition.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Unintended Pregnancy in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptives and bone mineral density: A population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Bone mineral density in postmenopausal women as determined by prior oral contraceptive use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

The reduction in risk of ovarian cancer associated with oral-contraceptive use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

A case-control study of oral contraceptive use and invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

The changes before 'the change'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptives: therapeutic uses and quality-of-life benefits--case presentations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptives and colorectal tumors. A review of epidemiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptives and colorectal cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Effects of an oral contraceptive combination containing 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on healthy premenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Biochemical aspects of hormonal contraception: effects on bone metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral-contraceptive use and risk of hip fracture: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Determinants of long-term hormone replacement therapy and reasons for early discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Stroke in users of low-dose oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Low-dose oral contraceptive use and the risk of myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

Oral contraceptive use in perimenopause

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900292-5

10.1016/S0010-7824(02)00292-5

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference